Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-up - 24/11/22
Doi : 10.1016/j.clinre.2022.102035
Clara Dassetto a, Patrick Borentain a, René Gérolami a, b, c, Philippe Colson b, c, d, ⁎ 
a Assistance Publique - Hôpitaux de Marseille (AP-HM), Service d'Hépato-Gastro-Entérologie, Unité Hépatologie, 264 rue Saint-Pierre, 13385 Marseille, France
b IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France
c Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Microbes Evolution Phylogeny and Infections (MEPHI), 27 boulevard Jean Moulin, 13005 Marseille, France
d Assistance Publique - Hôpitaux de Marseille (AP-HM), 264 rue Saint-Pierre, 13385 Marseille, France
⁎Corresponding author at: IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.IHU Méditerranée Infection19-21 boulevard Jean MoulinMarseille13005France
Keywords : Hepatitis delta, Bulevirtide, treatment, pegylated interferon, genotype
Il testo completo di questo articolo è disponibile in PDF.
Mappa
© 2022
Elsevier Masson SAS. Tutti i diritti riservati.
Vol 46 - N° 10
Articolo 102035- Dicembre 2022 Ritorno al numero
Articolo precedente
- Discontinuing directly acting antivirals during hepatitis C treatment: highlighting an infrequent but hostile event
- Mohamed El-Kassas, Sherif Elbehiry, Enas Rezk, Dalia Omran, Ahmed Sherief, Mohamed Eltabbakh, Inas Moaz, Adel TEl ahan, Mohammad Abdalgaber, Haidy Khalil, Mohamed Alboraie, Amr El Fouly, Mohammed Aboul-Ezz, Amany Wahb, Ahmed Madkour
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?